Isfahan University of Medical Sciences

Science Communicator Platform

Share By
Changes in the Level of Antiphospholipid Antibodies (Anticardiolipin and Anti‑Β2‑Glycoprotein‑I) and Thromboembolic Indices in Covid‑19 Patients During 3 Weeks Publisher

Summary: Do antiphospholipid antibodies explain clots in COVID-19? A study found no significant association with thromboembolic events, pointing to other mechanisms worth investigating. #COVID19 #Thrombosis

Haghighipour S ; Salesi M ; Keikhaei F ; Tarrahi M J ; Khani Z ; Salehi H
Authors

Source: International Journal of Preventive Medicine Published:2023


Abstract

Introduction: COVID‑19 is a respiratory disease caused by infection with severe acute respiratory syndrome Coronavirus 2 (SARS‑CoV‑2). Thrombotic complications appear to be of particular importance in patients with COVID‑19. This study aimed to investigate Changes in the level of Antiphospholipid antibodies (Anticardiolipin and Anti‑β2‑glycoprotein‑I) and thromboembolic indices in COVID‑19 patients during 3 weeks. Methods: This cross‑sectional study was performed on adults with Covid‑19 hospitalized at Al‑Zahra Hospital in Isfahan. The case group includes the patients admitted to the internal ward or ICU who despite receiving prophylactic or anticoagulant doses suffer from thrombotic complications and the control group includes COVID‑19 patients without thromboembolic events. The sample size of 120 people was considered. Anticardiolipin and anti‑β2‑glycoprotein‑I antibodies, coagulation profiles including Fibrinogen, PTT, PT Troponin, ESR, CRP, and D‑dimer were examined. After collection, the data were entered into spss24 software and analyzed. Results: The results showed that there was no statistically significant difference in the changes of anticardiolipin and anti‑beta‑2 glycoprotein in IgM and IgG as well as in the changes of ESR, CRP, PTT, PT, and fibrinogen in the two groups (P > 0.05). Conclusions: Our study showed that there was no statistically significant relationship between anti‑phospholipid antibodies (anticardiolipin and anti‑beta‑2 glycoprotein) and thromboembolic events. Therefore anticardiolipin and anti‑beta‑2 glycoprotein is probably the puzzles causing thrombosis in COVID‑19 patients, and other inflammatory responses should be examined among the cases. © 2023 International Journal of Preventive Medicine.
Related Docs
View other Related Docs
1. Evaluation of the Association Between Antiphospholipid Antibodies and Icu Admission Outcome in Critically Ill Covid-19 Patients in Iranian Population, International Journal of Preventive Medicine (2022)
2. New-Onset Acute Ischemic Stroke Following Covid-19: A Case-Control Study, Journal of Research in Medical Sciences (2022)
3. A Review of Pathophysiological Mechanism, Diagnosis, and Treatment of Thrombosis Risk Associated With Covid-19 Infection, IJC Heart and Vasculature (2022)
Experts (# of related papers)
View all Related Experts
Somayeh Sadeghi (2)
Mohammad Amin Najafi (2)
Changes in the Level of Antiphospholipid Antibodies (Anticardiolipin and Anti‑Β2‑Glycoprotein‑I) and Thromboembolic Indices in Covid‑19 Patients During 3 Weeks
Other Related Docs
4. On Admission Hemoglobin and Albumin, As the Two Novel Factors Associated With Thrombosis in Covid-19 Pneumonia, Journal of Renal Injury Prevention (2022)
5. An Investigation to Find the Correlation Between Lupus Anticoagulant and Coagulation Abnormalities in Covid-19 Patients; a Narrative Review, Journal of Nephropathology (2024)
6. Diagnosis and Treatment of Coagulopathy Caused by the New Coronavirus: A Systematic Review and Meta-Analysis Protocol, Advanced Biomedical Research (2023)
7. Correlation of Expression of Mmp-2, Ace2, and Tmprss2 Genes With Lymphopenia for Mild and Severity of Covid-19, Iranian Journal of Allergy, Asthma and Immunology (2023)
8. Diversity in the Clinical Course and Outcome of Covid‑19 in Patients With Different Inborn Errors of Immunity Can Be Associated With the Type of Error, Advanced Biomedical Research (2024)
9. A Mini-Review on Cardiovascular and Hematological Complications of Covid-19, Coronaviruses (2021)
10. Differential Diagnostic Utility of Clinical Laboratory Data in Patients With Severe and Non-Severe Covid-19, Shiraz E Medical Journal (2022)
11. Clinical Characteristics and Cardiovascular Risk Factors Associated With Clinical Outcome in Hospitalized Patients With Covid-19, Journal of Preventive Epidemiology (2023)
12. A Study on the Effect of Aspirin on Clinical Symptoms, Laboratory Indices, and Outcomes in Patients With Covid-19, Journal of Nephropharmacology (2023)
13. Incidence and Mortality of Covid-19 in Iranian Multiple Sclerosis Patients Treated With Disease-Modifying Therapies, Revue Neurologique (2025)
14. Different Sars-Cov-2 Subvariants and Coagulation Markers Trend: A Retrospective Multicentric Study From Iranian Network for Research in Viral Diseases (Inrvd), Health Science Reports (2026)
15. Risk Factors, Clinical, and Laboratory Characteristics of Patients With a Diagnosis of Covid-19, Journal of Emergency Practice and Trauma (2022)
16. Evaluation and Comparison of Treatment Response and In-Hospital Prognosis of Covid-19-Related Guillain-Barre Syndrome With Non-Covid-19 Patients, Medical Journal of the Islamic Republic of Iran (2025)
17. On-Admission Versus In-Hospital Thromboembolism Due to Covid-19 Infection. What Is the Particular Characteristic of Those With Early Thrombotic Events?, Advances in Respiratory Medicine (2021)
18. A Systematic Review on Post-Discharge Venous Thromboembolism Prophylaxis in Patients With Covid-19, Egyptian Heart Journal (2023)